Cargando…
Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
[Image: see text] Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356864/ https://www.ncbi.nlm.nih.gov/pubmed/30729224 http://dx.doi.org/10.1021/acsomega.8b02729 |
_version_ | 1783391657284075520 |
---|---|
author | Han, Zheng Sergeeva, Olga Roelle, Sarah Cheng, Han Gao, Songqi Li, Yajuan Lee, Zhenghong Lu, Zheng-Rong |
author_facet | Han, Zheng Sergeeva, Olga Roelle, Sarah Cheng, Han Gao, Songqi Li, Yajuan Lee, Zhenghong Lu, Zheng-Rong |
author_sort | Han, Zheng |
collection | PubMed |
description | [Image: see text] Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The probe consists of a small ZD2 peptide specific to EDB-FN and a (64)Cu-DOTA chelate. The probe was synthesized using standard solid-phase peptide chemistry and chelated to (64)Cu prior to imaging. PET images were acquired at 4 and 22 h after intravenously injecting a 200 μCi probe into mice bearing human PC3 and LNCaP tumors, which represent highly aggressive and slow-growing prostate tumors, respectively. At 4 and 22 h postinjection, tumors could be clearly identified in the PET images. A significant higher signal was observed in PC3 tumors than in LNCaP tumors at 22 h (p = 0.01). Probe accumulation was also higher in PC3 tumors at 24 h. These data demonstrated that PET molecular imaging of EDB-FN in the tumor microenvironment of prostate cancer allows efficient differentiation of PC3 and LNCaP tumors in vivo. The ZD2 peptide-targeted PET probe shows potential in the detection and characterization of high-risk prostate cancer to improve the clinical management of prostate cancer. |
format | Online Article Text |
id | pubmed-6356864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-63568642019-02-04 Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer Han, Zheng Sergeeva, Olga Roelle, Sarah Cheng, Han Gao, Songqi Li, Yajuan Lee, Zhenghong Lu, Zheng-Rong ACS Omega [Image: see text] Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The probe consists of a small ZD2 peptide specific to EDB-FN and a (64)Cu-DOTA chelate. The probe was synthesized using standard solid-phase peptide chemistry and chelated to (64)Cu prior to imaging. PET images were acquired at 4 and 22 h after intravenously injecting a 200 μCi probe into mice bearing human PC3 and LNCaP tumors, which represent highly aggressive and slow-growing prostate tumors, respectively. At 4 and 22 h postinjection, tumors could be clearly identified in the PET images. A significant higher signal was observed in PC3 tumors than in LNCaP tumors at 22 h (p = 0.01). Probe accumulation was also higher in PC3 tumors at 24 h. These data demonstrated that PET molecular imaging of EDB-FN in the tumor microenvironment of prostate cancer allows efficient differentiation of PC3 and LNCaP tumors in vivo. The ZD2 peptide-targeted PET probe shows potential in the detection and characterization of high-risk prostate cancer to improve the clinical management of prostate cancer. American Chemical Society 2019-01-14 /pmc/articles/PMC6356864/ /pubmed/30729224 http://dx.doi.org/10.1021/acsomega.8b02729 Text en Copyright © 2019 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Han, Zheng Sergeeva, Olga Roelle, Sarah Cheng, Han Gao, Songqi Li, Yajuan Lee, Zhenghong Lu, Zheng-Rong Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer |
title | Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate
as a Positron Emission Tomography Probe for Detection
and Characterization of Prostate Cancer |
title_full | Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate
as a Positron Emission Tomography Probe for Detection
and Characterization of Prostate Cancer |
title_fullStr | Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate
as a Positron Emission Tomography Probe for Detection
and Characterization of Prostate Cancer |
title_full_unstemmed | Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate
as a Positron Emission Tomography Probe for Detection
and Characterization of Prostate Cancer |
title_short | Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate
as a Positron Emission Tomography Probe for Detection
and Characterization of Prostate Cancer |
title_sort | preparation and evaluation of zd2 peptide (64)cu-dota conjugate
as a positron emission tomography probe for detection
and characterization of prostate cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356864/ https://www.ncbi.nlm.nih.gov/pubmed/30729224 http://dx.doi.org/10.1021/acsomega.8b02729 |
work_keys_str_mv | AT hanzheng preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer AT sergeevaolga preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer AT roellesarah preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer AT chenghan preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer AT gaosongqi preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer AT liyajuan preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer AT leezhenghong preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer AT luzhengrong preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer |